[go: up one dir, main page]

ATE278014T1 - Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii - Google Patents

Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii

Info

Publication number
ATE278014T1
ATE278014T1 AT98964526T AT98964526T ATE278014T1 AT E278014 T1 ATE278014 T1 AT E278014T1 AT 98964526 T AT98964526 T AT 98964526T AT 98964526 T AT98964526 T AT 98964526T AT E278014 T1 ATE278014 T1 AT E278014T1
Authority
AT
Austria
Prior art keywords
obesity
target
type
atherosclerosis
treatment
Prior art date
Application number
AT98964526T
Other languages
English (en)
Inventor
Itzik Harosh
Original Assignee
Obe Therapy Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obe Therapy Biotechnology filed Critical Obe Therapy Biotechnology
Application granted granted Critical
Publication of ATE278014T1 publication Critical patent/ATE278014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98964526T 1997-12-30 1998-12-28 Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii ATE278014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716655A FR2773079B1 (fr) 1997-12-30 1997-12-30 Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
PCT/FR1998/002883 WO1999035257A1 (fr) 1997-12-30 1998-12-28 Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii

Publications (1)

Publication Number Publication Date
ATE278014T1 true ATE278014T1 (de) 2004-10-15

Family

ID=9515258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98964526T ATE278014T1 (de) 1997-12-30 1998-12-28 Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii

Country Status (7)

Country Link
US (1) US6942967B1 (de)
EP (1) EP1042463B1 (de)
AT (1) ATE278014T1 (de)
AU (1) AU1971399A (de)
DE (1) DE69826717T2 (de)
FR (1) FR2773079B1 (de)
WO (1) WO1999035257A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6910100A (en) * 1999-08-18 2001-03-13 Lawrence Chan Apolipoprotein b mrna-specific ribozyme
US20040115184A1 (en) * 2001-02-27 2004-06-17 Smith Harold C Methods and compositions for modifying apolipoprotein b mrna editing
AU2003257181A1 (en) * 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
FR2870855A1 (fr) * 2004-05-27 2005-12-02 Obe Therapy Biotechnology Soc Procede de criblage a haut debit pour l'identification de molecules inhibitrices de l'activite d'enzymes d'edition
KR100905419B1 (ko) 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762014B1 (fr) 1997-04-10 1999-06-04 Itzik Harosh Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs

Also Published As

Publication number Publication date
DE69826717D1 (de) 2004-11-04
EP1042463A1 (de) 2000-10-11
AU1971399A (en) 1999-07-26
EP1042463B1 (de) 2004-09-29
DE69826717T2 (de) 2006-02-23
US6942967B1 (en) 2005-09-13
WO1999035257A1 (fr) 1999-07-15
FR2773079B1 (fr) 2002-05-17
FR2773079A1 (fr) 1999-07-02

Similar Documents

Publication Publication Date Title
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ATE242003T1 (de) Enzyme zur behandlung von diabetes mellitus typ i
BR9814276A (pt) Antìgenos de superfìcie
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE69934110T8 (de) Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
ATE218064T1 (de) Immunogene tlp-zusammensetzung
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
WO2005005471A3 (en) Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
NARUSE et al. Microtubule assembly inhibitory factor from sea urchin egg cortex. Purification, some properties, and site of its action
ATE454472T1 (de) C1ckb-mutation als diagnostisches und therapeutisches ziel
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
AU3811395A (en) Identification of the p21waf1-pcna interaction site and therapeutic applications thereof
WO2005049063A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
NO20060581L (no) Fish protein hydrolyzate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties